| pubmed-article:7704483 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7704483 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:7704483 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7704483 | lifeskim:mentions | umls-concept:C0027627 | lld:lifeskim |
| pubmed-article:7704483 | lifeskim:mentions | umls-concept:C0023828 | lld:lifeskim |
| pubmed-article:7704483 | lifeskim:mentions | umls-concept:C1280477 | lld:lifeskim |
| pubmed-article:7704483 | lifeskim:mentions | umls-concept:C0205359 | lld:lifeskim |
| pubmed-article:7704483 | lifeskim:mentions | umls-concept:C1552617 | lld:lifeskim |
| pubmed-article:7704483 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:7704483 | lifeskim:mentions | umls-concept:C0282443 | lld:lifeskim |
| pubmed-article:7704483 | lifeskim:mentions | umls-concept:C0521116 | lld:lifeskim |
| pubmed-article:7704483 | lifeskim:mentions | umls-concept:C0284547 | lld:lifeskim |
| pubmed-article:7704483 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:7704483 | pubmed:dateCreated | 1995-5-11 | lld:pubmed |
| pubmed-article:7704483 | pubmed:abstractText | Targeted delivery of macrophage activating agents is an attractive approach to treat micrometastatic disease. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) is a potent activator of monocytes/macrophages in humans, mice, and dogs. We have conducted clinical trials in dogs with malignant and highly metastatic spontaneous tumors. Presented are results of our trials evaluating L-MTP-PE in combination with surgery and chemotherapy in dogs with spontaneous osteosarcoma and hemangiosarcoma, particularly relevant malignancies having having many similarities to human cancer. Osteosarcoma dogs received chemotherapy following surgery (cisplatin q 28 days x 4). At completion of chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p < 0.021). Dogs with splenic hemangiosarcoma received combination chemotherapy following surgery (doxorubicin and cyclophosphamide q 21 days x 4). At the first chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p < 0.03). These studies show that L-MTP-PE is an effective agent for treatment of metastasis and can be safely administered in combination with chemotherapy. | lld:pubmed |
| pubmed-article:7704483 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7704483 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7704483 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7704483 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7704483 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7704483 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7704483 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7704483 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7704483 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7704483 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7704483 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7704483 | pubmed:issn | 1061-186X | lld:pubmed |
| pubmed-article:7704483 | pubmed:author | pubmed-author:FoxL ELE | lld:pubmed |
| pubmed-article:7704483 | pubmed:author | pubmed-author:MacEwenE GEG | lld:pubmed |
| pubmed-article:7704483 | pubmed:author | pubmed-author:KellerE TET | lld:pubmed |
| pubmed-article:7704483 | pubmed:author | pubmed-author:KurzmanI DID | lld:pubmed |
| pubmed-article:7704483 | pubmed:author | pubmed-author:RosenthalR... | lld:pubmed |
| pubmed-article:7704483 | pubmed:author | pubmed-author:HelfandSS | lld:pubmed |
| pubmed-article:7704483 | pubmed:author | pubmed-author:LondonCC | lld:pubmed |
| pubmed-article:7704483 | pubmed:author | pubmed-author:ObradovichJJ | lld:pubmed |
| pubmed-article:7704483 | pubmed:author | pubmed-author:VailDD | lld:pubmed |
| pubmed-article:7704483 | pubmed:author | pubmed-author:KisseberthWW | lld:pubmed |
| pubmed-article:7704483 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7704483 | pubmed:volume | 2 | lld:pubmed |
| pubmed-article:7704483 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7704483 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:7704483 | pubmed:pagination | 391-6 | lld:pubmed |
| pubmed-article:7704483 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7704483 | pubmed:meshHeading | pubmed-meshheading:7704483-... | lld:pubmed |
| pubmed-article:7704483 | pubmed:meshHeading | pubmed-meshheading:7704483-... | lld:pubmed |
| pubmed-article:7704483 | pubmed:meshHeading | pubmed-meshheading:7704483-... | lld:pubmed |
| pubmed-article:7704483 | pubmed:meshHeading | pubmed-meshheading:7704483-... | lld:pubmed |
| pubmed-article:7704483 | pubmed:meshHeading | pubmed-meshheading:7704483-... | lld:pubmed |
| pubmed-article:7704483 | pubmed:meshHeading | pubmed-meshheading:7704483-... | lld:pubmed |
| pubmed-article:7704483 | pubmed:meshHeading | pubmed-meshheading:7704483-... | lld:pubmed |
| pubmed-article:7704483 | pubmed:meshHeading | pubmed-meshheading:7704483-... | lld:pubmed |
| pubmed-article:7704483 | pubmed:meshHeading | pubmed-meshheading:7704483-... | lld:pubmed |
| pubmed-article:7704483 | pubmed:meshHeading | pubmed-meshheading:7704483-... | lld:pubmed |
| pubmed-article:7704483 | pubmed:meshHeading | pubmed-meshheading:7704483-... | lld:pubmed |
| pubmed-article:7704483 | pubmed:meshHeading | pubmed-meshheading:7704483-... | lld:pubmed |
| pubmed-article:7704483 | pubmed:meshHeading | pubmed-meshheading:7704483-... | lld:pubmed |
| pubmed-article:7704483 | pubmed:meshHeading | pubmed-meshheading:7704483-... | lld:pubmed |
| pubmed-article:7704483 | pubmed:meshHeading | pubmed-meshheading:7704483-... | lld:pubmed |
| pubmed-article:7704483 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7704483 | pubmed:articleTitle | Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. | lld:pubmed |
| pubmed-article:7704483 | pubmed:affiliation | Department of Medical Sciences, University of Wisconsin, Madison 53706. | lld:pubmed |
| pubmed-article:7704483 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7704483 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7704483 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:7704483 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7704483 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7704483 | lld:pubmed |
